Oppenheimer Asset Management Inc. Sells 78,876 Shares of Zoetis Inc. $ZTS

Oppenheimer Asset Management Inc. reduced its stake in Zoetis Inc. (NYSE:ZTS) by 30.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 183,520 shares of the company’s stock after selling 78,876 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Zoetis were worth $23,090,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. grew its stake in shares of Zoetis by 12.9% in the 4th quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares during the period. Nordea Investment Management AB grew its stake in shares of Zoetis by 79.2% in the 4th quarter. Nordea Investment Management AB now owns 4,932,787 shares of the company’s stock valued at $622,222,000 after purchasing an additional 2,179,578 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Zoetis by 14.6% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after acquiring an additional 550,859 shares during the last quarter. Alliancebernstein L.P. grew its position in Zoetis by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock worth $620,595,000 after acquiring an additional 496,320 shares during the last quarter. Finally, Fundsmith LLP grew its position in Zoetis by 25.3% during the 3rd quarter. Fundsmith LLP now owns 3,615,131 shares of the company’s stock worth $528,966,000 after acquiring an additional 730,300 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research analyst reports. Citigroup initiated coverage on Zoetis in a research report on Wednesday, April 15th. They set a “buy” rating and a $145.00 price target on the stock. William Blair restated an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. Piper Sandler restated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a research report on Thursday, January 22nd. Leerink Partners restated a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Finally, Weiss Ratings downgraded Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Zoetis has an average rating of “Hold” and an average target price of $151.75.

Zoetis Stock Performance

ZTS stock opened at $115.10 on Friday. The company has a market cap of $48.42 billion, a P/E ratio of 19.12, a price-to-earnings-growth ratio of 1.75 and a beta of 0.98. Zoetis Inc. has a twelve month low of $112.97 and a twelve month high of $172.23. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The business’s fifty day moving average is $119.93 and its 200-day moving average is $124.79.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 12th. The company reported $1.48 EPS for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts forecast that Zoetis Inc. will post 7.02 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.